Sirolimus NDC 50268-718

NDC codes

FDA NDC Directory

Product NDC (as listed)50268-718Labeler and product segments. Claims need a package NDC.

Product NDC at billing width50268-0718Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
50268-718-13	50268071813	30 BLISTER PACK in 1 BOX (50268-718-13) / 1 TABLET in 1 BLISTER PACK (50268-718-11)Marketed from Apr 23, 2018

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Sirolimus
Generic name (nonproprietary): sirolimus
Active ingredients: Sirolimus — 1 mg/1
Dosage form: Tablet
Route: Oral
Labeler: AvPAK
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 201578
Marketing start: Apr 23, 2018
Listing expires: Dec 31, 2027
Other FDA classes: Decreased Immunologic Activity (Physiologic effect)Protein Kinase Inhibitors (Mechanism)mTOR Inhibitors (Mechanism)
Identifiers: Product ID 50268-718_4cb0eea7-6bbc-aef8-e063-6294a90a7887SPL ID 4cb0eea7-6bbc-aef8-e063-6294a90a7887SPL set ID 6a85ad01-8144-4d9c-e053-2991aa0a4f85RxCUI 349208UNII W36ZG6FT64
Pharmacologic class: Kinase Inhibitor; mTOR Inhibitor Immunosuppressant

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N450268071813 followed by a unit qualifier and the quantity

Package 50268-0718-13. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Mar 10, 2026. This label includes a boxed warning.

Indications (excerpt from the label)

Sirolimus is an mTOR inhibitor immunosuppressant indicated for the prophylaxis of organ rejection in patients aged ≥13 years receiving renal transplants. Patients at low-to moderate-immunologic risk: Use initially with cyclosporine (CsA) and corticosteroids.CsA withdrawal is recommended 2 to 4 months after transplantation (1.1) . Patients at high-immunologic risk: Use in combination with CsA and corticosteroids for the first 12 months following transplantation (1.1) . Safety and efficacy of CsA withdrawal has not been established in high risk patients (1.1 , 1.2 , 14.3 ). Sirolimus is an mTOR inhibitor indicated for the treatment of patients with lymphangioleiomyomatosis (1.3). 1.1 Prophylax…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 201578

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 201578
Product	Strength	Form · route	Labeler	Product NDC
Sirolimus	Sirolimus 1 mg/1	TabletOral	Dr. Reddy's Laboratories Limited	55111-653
Sirolimus	Sirolimus 2 mg/1	TabletOral	Dr. Reddy's Laboratories Limited	55111-654
Sirolimus	Sirolimus 1 mg/1	TabletOral	REMEDYREPACK INC.	70518-3795
Sirolimus	Sirolimus 1 mg/1	TabletOral	American Health Packaging	68084-915